<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moxidectin (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moxidectin (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Moxidectin (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="118187" href="/d/html/118187.html" rel="external">see "Moxidectin (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="118277" href="/d/html/118277.html" rel="external">see "Moxidectin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F51582426"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anthelmintic</span></li></ul></div>
<div class="block dop drugH1Div" id="F51637553"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3301ffe-bd94-4e4f-9064-281b540a067b">Onchocerciasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onchocerciasis:</b> Children ≥12 years and Adolescents: Oral: 8 mg as a single dose</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51582450"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51582451"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F51637552"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="118187" href="/d/html/118187.html" rel="external">see "Moxidectin (United States: Not available): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3301ffe-bd94-4e4f-9064-281b540a067b">Onchocerciasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onchocerciasis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For individuals from <i>Loa loa–</i>endemic areas, rule out co-infection prior to moxidectin administration to avoid life-threatening encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 8 mg as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F51637555"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute or ESRD: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F51637556"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F51600361"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (39%), postural orthostatic tachycardia (34%), hypotension (30%), orthostatic hypotension (22%), peripheral edema (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (58%), chills (≤27%), lymph node pain (13%), dizziness (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (65%), skin rash (37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (31%), diarrhea (≤15%), enteritis (≤15%), gastroenteritis (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (18% to 74%; severe: 18%), lymphocytopenia (48%: grade 3: 23%), leukocytosis (25%), neutropenia (20%: grade 4: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (64%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (23%), cough (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤27%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Symptomatic orthostatic hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinopenia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (3%), increased serum alanine aminotransferase (1%), increased serum aspartate aminotransferase (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain (8%), eye pruritus (7%), visual impairment (3%; including blurred vision, low vision acuity), allergic conjunctivitis (2%), eyelid edema (2%), conjunctival hyperemia (≤2%), ocular hyperemia (≤2%), increased lacrimation (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Mazzotti reaction</p></div>
<div class="block coi drugH1Div" id="F51558155"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F51637504"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Mazzoti reaction: Moxidectin treatment may cause cutaneous, ophthalmological, and/or systemic reactions (Mazzoti reaction) of varying severity, due to allergic and inflammatory host responses to the death of microfilariae. These reactions generally occur and resolve in the first week post-treatment. Risk may be increased in patients with higher microfilarial burden. Treatment of severe Mazzoti reactions is not definitive, but includes supportive care (eg, hydration and/or parenteral corticosteroids) to treat postural hypotension. Antihistamines and/or aspirin have been used for most mild to moderate reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: Orthostatic hypotension may occur, most commonly on the first 1 to 2 days after treatment. Decrease in blood pressure was transient and managed by resuming recumbency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Loiasis: Pretreatment assessment for loiasis is recommended in any patient with exposure to <i>Loa loa</i>-endemic areas; serious, sometimes fatal, encephalopathy may occur following treatment with moxidectin in onchocerciasis patients with concomitant loiasis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperreactive onchodermatitis: Patients with hyperreactive dermatitis (sowda) may be at increased risk for severe edema and worsening of onchodermatitis following treatment with moxidectin.</p></div>
<div class="block prod-avail drugH1Div" id="F51558150"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">There are no plans for commercial distribution of moxidectin in the US. Product will be available for onchocerciasis endemic parts of the world.</p></div>
<div class="block foc drugH1Div" id="F52532039"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral</p>
<p style="text-indent:2em;margin-left:2em;">Generic: 2 mg [500s] [contains lactose, sodium lauryl sulfate]</p></div>
<div class="block admp drugH1Div" id="F52614677"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to food</p></div>
<div class="block adm drugH1Div" id="F51637558"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals.</p></div>
<div class="block sts drugH1Div" id="F51637543"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store below 30°C (86°F). Protect from light. Once opened, administer within 24 hours. Discard unused tablets.</p></div>
<div class="block usep drugH1Div" id="F53571471"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of onchocerciasis due to <i>Onchocerca volvulus</i> (FDA approved in ages ≥12 years and adults). <b>Note:</b> Moxidectin tablets do not kill adult <i>O. volvulus</i>.</p></div>
<div class="block cyt drugH1Div" id="F51559849"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51559846"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53579111"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant were required to use long-acting contraception during clinical studies (Awadzi 2014; Korth-Bradley 2011), likely due to the long terminal half-life of moxidectin.</p></div>
<div class="block pri drugH1Div" id="F51637502"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571472"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Skin microfilarial counts; screening for loiasis prior to treatment in patients exposed to <i>Loa loa</i>-endemic areas; signs and symptoms of Mazzotti reaction, including symptomatic orthostatic hypotension</p></div>
<div class="block pha drugH1Div" id="F51637544"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Moxidectin, an anthelminthic agent, is active against the microfilariae of <i>O. volvulus</i>, but not effective in killing the adult worms. Studies with other nematodes suggest moxidectin binds to glutamate-gated chloride ions channels, gamma-aminobutyric acid (GABA) receptors, and/or APT-binding cassette transporters. This leads to increased permeability, influx of chloride ions, hyperpolarization, and muscle paralysis. There is also a reduction in motility of all stages of the parasite, excretion of immunomodulatory proteins, and the fertility of both male and female adult worms.</p></div>
<div class="block phk drugH1Div" id="F51637545"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 2,421 ± 1,658 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Unknown</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 23.3 days (559 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 2% (as unchanged drug)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24968000">
<a name="24968000"></a>Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. <i>PLoS Negl Trop Dis</i>. 2014;8(6):e2953. doi: 10.1371/journal.pntd.0002953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxidectin-united-states-not-available-pediatric-drug-information/abstract-text/24968000/pubmed" id="24968000" target="_blank">24968000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896908">
<a name="21896908"></a>Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. <i>Antimicrob Agents Chemother</i>. 2011;55(11):5200-5204. doi: 10.1128/AAC.00311-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxidectin-united-states-not-available-pediatric-drug-information/abstract-text/21896908/pubmed" id="21896908" target="_blank">21896908</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Moxidectin [prescribing information]. Melbourne, Victoria, Australia: Medicines Development for Global Health; March 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118396 Version 27.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
